Alector (Alector) FCF Margin %

: -304.83% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alector's Free Cash Flow for the three months ended in Dec. 2023 was $-46.30 Mil. Alector's Revenue for the three months ended in Dec. 2023 was $15.19 Mil. Therefore, Alector's FCF Margin % for the quarter that ended in Dec. 2023 was -304.83%.

As of today, Alector's current FCF Yield % is -38.43%.

The historical rank and industry rank for Alector's FCF Margin % or its related term are showing as below:

ALEC' s FCF Margin % Range Over the Past 10 Years
Min: -3664.18 Med: -344.72 Max: 453.73
Current: -192.19

During the past 8 years, the highest FCF Margin % of Alector was 453.73%. The lowest was -3664.18%. And the median was -344.72%.

ALEC's FCF Margin % is ranked worse than
53.55% of 1029 companies
in the Biotechnology industry
Industry Median: -149.8 vs ALEC: -192.19

Alector FCF Margin % Historical Data

The historical data trend for Alector's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-539.95

-814.13

142.60

-18.30

-192.19

Alector Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																-344.12	-299.55	-78.67	-509.89	-304.83

Competitive Comparison

For the Biotechnology subindustry, Alector's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alector FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, Alector's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alector's FCF Margin % falls into.

Alector FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alector's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-186.543	/	97.062
	=	-192.19 %

Alector's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-46.303	/	15.19
	=	-304.83 %

Alector FCF Margin % Related Terms

Thank you for viewing the detailed overview of Alector's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alector (Alector) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0Z2:Germany

Address

131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080

Website

https://www.alector.com

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Executives

Sara Kenkare-mitra	officer: President and Head of R&D	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano	officer: Chief Medical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal	director, officer: Chief Executive Officer	C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso	officer: Chief Financial Officer	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Terrance Mcguire	director, 10 percent owner	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Polaris Venture Management Co. Vi, L.l.c.	10 percent owner	ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Tillman U. Gerngross	director	C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr	director	C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner	director	C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Robert King	officer: Chief Development Officer	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman	officer: President and COO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080